Replimune Shares Rise Following Positive FDA Advisory Committee Vote
Replimune (REPL) shares surged more than double in post-market trading after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted positively on its lead asset RP1. The vote is a significant step toward potential regulatory approval for Replimune’s therapy. The favorable outcome from the advisory committee comes ahead of an August 2 decision by the FDA regarding full approval. This development has generated optimism among investors, highlighting progress in the company's clinical pipeline and its prospects in oncology treatments.
Tickers: $REPL
Topics: biotech clinical asset approval FDA advisory committee